Microsoft word - curriculum vitae december 2011.doc

Peter D’Arcy Sutherland
Peter Sutherland
Dr Peter D’Arcy Sutherland MBBS, FRACS (Urology) Married to wife Mary, since 1981. Two children, Julia and Henry. Commenced at University of Adelaide Medical School Passed Fellowship in Urology Examination Peter Sutherland
Basic Surgical Training, Royal Adelaide Hospital Appointed to Urological Training Post, Royal Adelaide Hospital Advanced Trainee (Urology), Royal Adelaide Hospital under the guidance of Mr John Maddern, (Head of Unit 1980-1981). Advanced Trainee (Urology), Flinders Medical Centre under the guidance of Professor Villis Marshall. Appointed to Institute of Urology, London as Clinical Assistant with Dean of the Institute, Mr John Pryor. This Fellowship was principally in the area of Andrology which was Mr Pryor’s main area of interest. Appointed to UCLA Medical Centre as a Foreign Fellow under the guidance of Dr J Kauffmann, Chief of Urology. Again, the main focus of this appointment was in the area of Andrology. Appointed as a Visiting Medical Specialist in Urology at Flinders Medical Centre, Adelaide under the guidance of Professor Villis Marshall. Appointed as a Senior Visiting Medical Specialist in Urology at the Royal Adelaide Hospital, Adelaide. Appointed as Head of the Urology Unit at the Royal Adelaide Hospital, Adelaide. Commenced private practice in Adelaide, South Australia. Principal interests include Andrology and Prostate Disease. The practice has set up Australasia’s first private specialist day surgery managing only urological conditions. Peter Sutherland
PROFESSIONAL REGISTRATIONS AND MEMBERSHIPS
South Australian Medical Board, Registered since 1977 Royal Australasian College of Surgeons, Fellow since 1983 BOARDS and POSITIONS HELD 1988 President of the Urological Society in South Australia. Appointed to the Australasian Board of Urology. National Advisory Board Member for: Pfizer and Viagra, Pharmacia and Caverject, Abbott and Uprima, Eli Lilly and Cialis, AMS and their penile prosthetic devices Bayer-GSK and Levitra. Astra Zeneca, Zoladex and Cosudex Device Technology and the daVinci Robot Principal Surgeon, Robotic Surgical Programme, Royal Adelaide Hospital. Mentor surgeon, Robotic Surgical Programme, Mentor surgeon, Robotic Surgical Programme, St Vincent’s Hospital, Sydney, Australia. Mentor surgeon, Robotic Surgical Programme, St Vincent’s Hospital, Sydney, Australia. Mentor surgeon, Robotic Surgical Programme, Tauronga Hospital, New Zealand. Mentor surgeon, Robotic Surgical Programme, Mentor surgeon, Robotic Surgical Programme, Mentor surgeon, Greenslopes Private Hospital. Mentor Surgeon, Greenslopes Private Hospital. Mentor Surgeon, Wesley Hospital, Brisbane Mentor Surgeon, East Kent Hospital, United Kingdom. Mentor Surgeon, Cabrini Hospital, Melbourne. Mentor Surgeon, St Vincent’s Hospital, Sydney. Peter Sutherland
International Society of Sexual Medicine Society of Robotic Surgery – Charter Member World Robotic Institute, Orlando, Florida Australian Prostate Cancer Bio-Resource Consortium Asia-Pacific Society for Sexual & Impotence Research Prostate Cancer Foundation of Australia – DVD – ‘A guide for men & their partners living Men’s Health Speaker Program – Prostate Cancer Foundation of Australia. daVinci Master Class, Australasian Prostate Cancer Conference, Melbourne. daVinci Master Class, Australasian Prostate Cancer Conference, Melbourne. Peter Sutherland
PRINCIPAL INVESTIGATOR IN THE FOLLOWING TRIALS

1. PFIZER A3711044 – A multi-center, randomized, parallel group, double-blind, placebo
controlled proof of concept and dose ranging study with an active control to assess the efficacy and safety/tolerability of UK-369,003 immediate release (IR) and modified release (MR) in the treatment of men with lower urinary tract symptoms (LUTS) with and without erectile dysfunction (ED). 2. Pfizer A1481119 – An international, multicenter, randomized, parallel group, double-blind, placebo-controlled, flexible dose escalation study to evaluate self-esteem and overall relationships in men with erectile dysfunction treated with viagra (sildenafil citrate) 3. Lilly H6D-MC-LVHG-2007 – A randomised, double-blind, placebo-controlled, parallel- design, 5-group multinational study to evaluate the efficacy, dose response, and safety of tadalafil once-a-day dosing for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia. 4. PPD SP583- A Phase 3, Parallel Group, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects with Overactive Bladder Syndrome. 5. PPD Yamanouchi Tamulosin Study –Tamsulosin with Benign Prostatic Hyperplasia (02- 6. Pfizer A1371041- Darifenacin in UUI - A1371041 long term, open label, multicentre study of darifenacin in subjects with overactive bladder. 7. Novartis A1371042 – Darifenacin Extension Study – A long-term open label, multicentre study of darifenacin in subjects with overactive bladder (urge Urinary Incontinence). 8. Pfizer A1371013 – Darifenacin 9. Pfizer A3871014 – UK-390,957 in premature ejaculation 10. Pfizer A3711030- UK-369,003 in erectile dysfunction 11. Eli Lilly H6D- VI- LVFH : Switching from sildenafil citrate to tadalafil in treatment of erectile dysfunction: multinational assessment of treatment preference. 12. Pfizer A1481195 – Viagra erectile dysfunction 13. Pfizer A3871027 – A Phase 2B, multi-centre, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. 14. GSK Vardenafil SB-7825258-001- A randomised, double-blind, parallel-group, placebocontrolled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in flexible-dose regimen compared to placebo in male erectile dysfunction subjects of broad etiology previously unresponsive to sildenafil therapy by history. Peter Sutherland
15. Pfizer A3871028 – A Phase 2 multi-centre, open-label, long-term extension trial to assess thesafety of oral UK-390,957 , administered as required in adult men with premature ejaculation. 16. Urogene OAB study- A multi-centre, randomised, double-blind, parallel group, Phase II efficacy study of HP749 20mg twice-daily versus placebo in patients with overactive bladder (OAB). 17. GSK ARI40006 – A randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety of Dutasteride 0.5mg administered once daily for four years to reduce the risk of biopsy-detectable prostate cancer. 18. Bayer – Potent II 12094 - Pivotal phase III trial to investigate the efficacy and safety of an orodispersible tablet vardenafil versus placebo in the treatment of men with erectile dysfunction (ED) – a fixed-dose, double-blind, randomized multi-centre trial – POTENT II 19. Novartis CZOL446E2432- Zometa for androgen-sensitive advanced prostate cancer – the 20. Eli Lilly H6D-CR-S024 – A Comparison of psychosocial outcomes following tadalafil once a day or PDE5 inhibitor as needed in men with erectile dysfunction. 21. Allergan 191622-082-01- A placebo-controlled, randomized, safety and efficacy study of BOTOXÒ (Botulinum Toxin Type A) purified neurotoxin complex in patients with neurogenic detrusor overactivity and neurological respiratory impairment. 22. Eli Lily H6D-MC-LVID – A Phase 3, randomized, double-blind, placebo-controlled, parallel- design, global multicenter study to evaluate the efficacy and safety of tadalafil once daily dosing for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia. 23. Eli Lilly I1A-MC-BPAE(a) – A phase 2, clinical study to evaluate daily oral doses of LY500307 for 24 weeks in men with lower urinary tract symptoms (LUTS) and prostatic enlargement secondary to benign prostatic hyperplasia (BPH). 24. Merck Sharp & Dohme MK4618-008 – A phase IIb randomized, placebo- and active comparator (tolterodine)-controlled, 2 part clinical study of the efficacy and safety of MK-4618 in patients with overactive bladder (OAB). PUBLICATIONS 1. Sutherland PD, Matson PL, Masters JR, Pryor JP. Association between infertility following reversal of vasectomy and the presence of sperm agglutinating activity in semen. Int J Androl. 1984;7:503-8. 2. Sutherland PD, Maddern JP, Jose JS, Marshall VR. Urethral stricture after cardiac 3. Sutherland PD, Landon GV, Matson PL, Pryor JP. Round headed sperm. Br J Urol. Peter Sutherland
4. Sutherland PD, Howard PR, Marshall VR. Colonic infarction following ethanol embolisation of the kidney. Br J Urol. 1986;58:337. 5. Gallus A, Murphy W, Nacey J, Morris M, Sutherland P, Marshall V, Magnani H. The influence of Org 10172, and antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy. Thromb Res. 1989;56:229-38. 6. Maddern GJ, Sutherland PD. Laparoscopic exploration for a presumed intra-abdominal testicle.Endosc Surg Allied Technol. 1994;2:293. 7. Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 1999 ;59:2324-8. 8. Tooher R, Sutherland P, Costello A, Gilling P, Rees G, Maddern G. A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia. J. Urol. 2004;171:1773-81. 9. McMahon CG, Stuckey BG, Lording DW, Wittert GA, Murphy A, Shin J, Sutherland PD,Palmer NR, Lowy MP, Jesudason DR, Fredlund P. A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. Int J Clin Pract. 2005;59:143-9. 10. Borg M, Sutherland P, Stapleton A, Bolt J, Steele D, Landers B, Porter A, Buxton S, Heilbornn C, Wong HZ. Outcome of post-prostatectomy radiotherapy in one institution. Australas Radiol. 2006;50:475-80. 11. Lowy M, Collins S, Bloch M, Gillman M, Lording D, Sutherland P, Wang H, Stecher V. Quality of erection questionnaire correlates: change in erection quality with erectile function,hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction. J Sex Med. 2007;4:83-92. 12. Ludbrook G, Sutherland P. Erroneous pulse oximetry readings during robotic prostatectomy. Anaesth Intensive Care. 2007; 35:144-5. 13. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of once-daily Tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. Eur Urol. 2009;56:727-35. 14. Ricciardelli C, Bianco-Miotto T, Jindal S, Dodd TJ, Cohen PA, Marshall VR, Sutherland PD, Samaratunga H, Kench JG, Dong Y, Wang H, Clements JA, Risbridger GP, Sutherland RL, Tilley WD, Horsfall DJ; Australian Prostate Cancer BioResource. Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiol Biomarkers Prev., 2010, 19, 1755-1765. 15. Centenera MM, Gillis J, Hanson A, Sutherland P, Australian Prostate CancerBioresource, Tilley WD, Butler LM. Anti-proliferative activity of novel synthetic Hsp90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer explants. IJC, for submission.

Source: http://www.sturology.com.au/pdfs/Peter%20Sutherland%20CV.pdf